Scarica l'app Stockscreener
100.34
2.37%
-2.44
Dopo l'orario di chiusura:
100.34
Precedente Chiudi:
$102.78
Aprire:
$102.11
Volume 24 ore:
610.72K
Relative Volume:
0.59
Capitalizzazione di mercato:
$6.18B
Reddito:
$3.99B
Utile/perdita netta:
$463.16M
Rapporto P/E:
14.13
EPS:
7.1
Flusso di cassa netto:
$1.10B
1 W Prestazione:
-1.39%
1M Prestazione:
-27.69%
6M Prestazione:
-11.30%
1 anno Prestazione:
-8.73%
Intervallo 1D:
$98.96
$102.48
Intervallo di 1 settimana:
$98.96
$104.53
Portata 52W:
$95.49
$148.06
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Nome
Jazz Pharmaceuticals Plc
Settore
Industria
Telefono
353-1-634-7800
Indirizzo
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Confronta JAZZ con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
100.34 | 6.18B | 3.99B | 463.16M | 1.10B | 7.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-02-26 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Iniziato | Goldman | Buy |
| 2024-01-03 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-27 | Downgrade | UBS | Buy → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Mkt Perform |
| 2023-06-12 | Ripresa | Wells Fargo | Equal Weight |
| 2022-12-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Buy |
| 2022-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-11-19 | Ripresa | Goldman | Buy |
| 2021-10-07 | Ripresa | Jefferies | Buy |
| 2021-10-05 | Iniziato | Citigroup | Buy |
| 2021-09-23 | Iniziato | Needham | Buy |
| 2021-05-19 | Ripresa | JP Morgan | Overweight |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-03 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-11-03 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-09 | Reiterato | H.C. Wainwright | Buy |
| 2020-09-14 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Iniziato | Jefferies | Buy |
| 2020-03-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Neutral |
| 2019-08-21 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2018-12-14 | Iniziato | Wolfe Research | Peer Perform |
| 2018-11-08 | Reiterato | B. Riley FBR | Buy |
| 2018-08-08 | Reiterato | Stifel | Buy |
| 2018-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Reiterato | H.C. Wainwright | Neutral |
| 2018-03-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
Mostra tutto
Jazz Pharmaceuticals Plc Borsa (JAZZ) Ultime notizie
Jazz Pharmaceuticals Completes $935 Million Acquisition of Chimerix - marketscreener.com
Jazz Pharmaceuticals Completes Acquisition of Chimerix - TipRanks
Jazz Pharmaceuticals acquires Chimerix for $935 million - Investing.com
Jazz's $935M Chimerix Buyout Targets First-Ever Treatment for Rare Brain Cancer, FDA Verdict Looms - Stock Titan
JAZZ vs. HRMY: Which Neuroscience Drugmaker Is the Stronger Play? - Yahoo Finance
JAZZ Vs. HRMY: Which Neuroscience Drugmaker Is The Stronger Play? - Barchart.com
Jazz Sues Alvogen Seeking to Block Copy of Defitelio Liver Drug - Bloomberg Law News
JAZZ vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Why Jazz Pharmaceuticals (JAZZ) is a Top Value Stock for the Long-Term - Yahoo Finance
Is Jazz Pharmaceuticals A Top Cannabis Investment For 2025? - Barchart.com
Is Jazz Pharmaceuticals a Top Cannabis Investment for 2025? - Zacks Investment Research
Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - GlobeNewswire Inc.
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers - Yahoo Finance
Drug Resistant Epilepsy Market reached US$ 0.78 billion in 2022 - openPR.com
Pharma 50: The top pharma companies in the world for 2025 - drugdiscoverytrends.com
Idiopathic Hypersomnia Treatment Market Set to Witness - openPR.com
Jazz Agrees To Fork Out $145m To Resolve Most Xyrem ‘Pay-For-Delay’ Claims - insights.citeline.com
BofA maintains Buy on Jazz Pharmaceuticals stock, target at $213 By Investing.com - Investing.com UK
Where Jazz Pharmaceuticals Stands With Analysts - Benzinga
Jazz (JAZZ) Moves 7.1% Higher: Will This Strength Last? - Nasdaq
Jazz Pharmaceuticals stock hits 52-week low at $99 By Investing.com - Investing.com Canada
Jazz Pharma inks $145M deal to resolve Xyrem antitrust claims - MSN
Jazz Pharmaceuticals at Needham Conference: Strategic Growth Insights By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals (JAZZ) Settles Antitrust Claims for $145M - GuruFocus
Jazz Pharma stock slips after $145M antitrust deal (JAZZ) - Seeking Alpha
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time To Buy Or Sell? - Barchart.com
Jazz Pharmaceuticals stock hits 52-week low at $99 - Investing.com
JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? - Yahoo Finance
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny - simplywall.st
Jazz Agrees To Pay $145M To Settle Xyrem Antitrust Fight - Law360
UBS cuts Jazz Pharmaceuticals stock price target to $166 By Investing.com - Investing.com UK
Potential Tariffs Pose Challenges for Jazz Pharmaceuticals (JAZZ) - GuruFocus
RBC Raises Price Target on Jazz Pharmaceuticals to $182 From $178, Keeps Outperform Rating - MarketScreener
Post-traumatic Stress Disorder Treatment Market Generated - openPR.com
After a year of 4.3% returns, Jazz Pharmaceuticals plc's (NASDAQ:JAZZ) share price drop last week may have less of an impact on institutional investors - Yahoo Finance
JAZZ or ARGX: Which Is the Better Value Stock Right Now? - Yahoo Finance
Teacher Retirement System of Texas Buys 2,346 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) - MarketBeat
Is Jazz Pharmaceuticals (JAZZ) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
10 Best Mid Cap Biotech Stocks to Buy - Insider Monkey
Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference - Eagle-Tribune
Dravet Syndrome Market Expected to Experience Major Growth - openPR
Is Jazz Pharmaceuticals plc (JAZZ) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Focal Epilepsy Market: Analysis of Epidemiology, Pipeline - openPR
Axsome's ADHD drug meets main goal in late-stage study - Marketscreener.com
12 Most Promising Biotech Stocks According to Wall Street Analysts - Insider Monkey
Why Jazz Pharmaceuticals (JAZZ) is a Top Momentum Stock for the Long-Term - Yahoo Home
Jazz strikes the chord with $935m Chimerix acquisition - BioXconomy
Based On Its ROE, Is Jazz Pharmaceuticals plc (NASDAQ:JAZZ) A High Quality Stock? - simplywall.st
Jazz Pharmaceuticals Plc Azioni (JAZZ) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):